Keigo Machida is an associate professor of molecular microbiology and immunology at the University of Southern California Keck School of Medicine. He is developing improved methodology for biomarker-guided, repurposed, FDA-approved drug therapy for liver cancer. Liver cancer incidence increases while many other cancer incidence decreases. Liver cancer patients have circulating tumor cells (CTCs) in the blood. By testing genetic mutations and messenger RNA levels of CTCs and various drug response rates, the best available therapy can be selected for each patient. Keigo holds a Ph.D. from the University of Tokyo School of Medicine.